Oxidative stress in brain aging - Implications for therapeutics of neurodegenerative diseases

被引:661
作者
Floyd, RA
Hensley, K
机构
[1] Oklahoma Med Res Fdn, Free Radical Biol Aging Res Program, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA
关键词
8-oxo guarosine; Alzheimer's disease; brain aging; cognitive impairment; hydroxynonenal; isoprostanes; neuroinflammation; nitrones; oxidative damage; protein oxidation; stroke; vitamin E;
D O I
10.1016/S0197-4580(02)00019-2
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Age has a powerful effect on enhanced susceptibility to neurodegenerative diseases, including susceptibility to stroke and cognitive impairment (CI) even in optimally healthy individuals. We critically evaluated the notion that oxidative stress increases in aging brain. Rigorous studies show logarithmic age-dependent increases in oxidized proteins and oxidized DNA lesions. Decreased activity of antioxidant protective enzymes does not account for the observed increases. The reactivity of the lipid oxidation product 4-hydroxy-2-nonenal (HNE) with key mitochondria enzymes may be important in the age-dependent loss in energy generation and enhanced susceptibility of neurons to apoptosis. Age-dependent enhanced neuroinflammatory processes may play an important role in toxin generation that causes death or dysfunction of neurons in neurodegenerative diseases. Non-steroidal anti-inflammatory drugs (NSAIDs) show significant promise. Vitamin E supplementation did not show major beneficial effect on cognitive functions. Major clinical trials for Alzheimer's disease (AD) involving cycloxygenase-II (COX II) inhibitors and amyloid-beta vaccination have been discontinued. Novel therapeutics based on blocking neuron damaging neuroinflammatory processes show great promise for abating dementia progression although they have yet to make it to clinical practice. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:795 / 807
页数:13
相关论文
共 125 条
[51]  
2-S
[52]  
Hensley K, 1998, J NEUROCHEM, V71, P2549
[53]  
Hensley K, 1998, J NEUROSCI, V18, P8126
[54]   p38 kinase is activated in the Alzheimer's disease brain [J].
Hensley, K ;
Floyd, RA ;
Zheng, NY ;
Nael, R ;
Robinson, KA ;
Nguyen, X ;
Pye, QN ;
Stewart, CA ;
Geddes, J ;
Markesbery, WR ;
Patel, E ;
Johnson, GVW ;
Bing, GY .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (05) :2053-2058
[55]   CPI-1189 inhibits interleukin 1β-induced p38-mitogen-activated protein kinase phosphorylation:: an explanation for its neuroprotective properties? [J].
Hensley, K ;
Robinson, KA ;
Pye, QN ;
Floyd, RA ;
Cheng, I ;
Garland, WA ;
Irwin, I .
NEUROSCIENCE LETTERS, 2000, 281 (2-3) :179-182
[56]  
HENSLEY K, 1999, OXIDAT STRESS DIS, V2, P311
[57]   Selective inactivation of α-ketoglutarate dehydrogenase and pyruvate dehydrogenase:: Reaction of lipoic acid with 4-hydroxy-2-nonenal [J].
Humphries, KM ;
Szweda, LI .
BIOCHEMISTRY, 1998, 37 (45) :15835-15841
[58]   Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease [J].
in 't Veld, BA ;
Ruitenberg, A ;
Hofman, A ;
Launer, LJ ;
van Duijn, CM ;
Stijnen, T ;
Breteler, MMB ;
Stricker, BHC .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (21) :1515-1521
[59]   Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease [J].
Janus, C ;
Pearson, J ;
McLaurin, J ;
Mathews, PM ;
Jiang, Y ;
Schmidt, SD ;
Chishti, MA ;
Horne, P ;
Heslin, D ;
French, J ;
Mount, HTJ ;
Nixon, RA ;
Mercken, M ;
Bergeron, C ;
Fraser, PE ;
St George-Hyslop, P ;
Westaway, D .
NATURE, 2000, 408 (6815) :979-982
[60]  
JORGENSEN OS, 1990, J NEUROL SCI, V98, P63